Brca1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{Infobox
|type=protein
|image=
|title=BRCA1 Protein
|gene=BRCA1 (Breast Cancer 1)
|uniprot=P38398
|location=Nucleus, cytoplasm
|molecular_weight=220 kDa
|function=DNA repair, genome stability, transcriptional regulation
|diseases=Breast cancer, Ovarian cancer, Fanconi anemia
}}
BRCA1 (Breast Cancer 1) is a tumor suppressor protein that plays a central role in maintaining genomic stability through DNA repair, cell cycle control, and transcriptional regulation. The BRCA1 protein is encoded by the BRCA1 gene on chromosome 17q21 and is expressed in most tissues, with particularly high levels in breast and ovarian cells. Germline mutations in BRCA1 predispose individuals to early-onset breast and ovarian cancers.
The BRCA1 protein contains multiple functional domains:
- RING Domain: E3 ubiquitin ligase activity at N-terminus
- BRCT Domains: Two tandem breast cancer C-terminal domains for DNA binding
- ** coiled-coil Domain**: Interaction with PALB2 and BRCA2
- Transactivation Domain: Transcriptional activation at C-terminus
- Homologous Recombination (HR): Central coordinator of error-free DNA repair
- DNA Double-Strand Break Sensing: Rapid recruitment to DNA damage sites
- Checkpoint Activation: Cell cycle arrest via Chk2 and Chk1
- Genome Surveillance: Global genome stability maintenance
- End Resection: Initiation of HR through DNA end processing
- Rad51 Filament Formation: Loading Rad51 onto single-stranded DNA
- Sister Chromatid Exchange: Regulation of SCE rates
- Fanconi Anemia Pathway: Interacts with FA proteins
- p53 Co-activator: Enhances p53-mediated transcription
- RNA Polymerase II Regulation: Modulates transcription elongation
- Chromatin Remodeling: Interaction with histone modifiers
- Stress Response Genes: Activation of stress-responsive genes
- DNA Damage Accumulation: Impaired DNA repair in AD neurons
- Cell Cycle Re-entry: Abnormal cell cycle activation
- Therapeutic Implications: BRCA1 enhancement strategies
- Oxidative Stress Response: Protection against oxidative DNA damage
- Mitochondrial Function: Mitochondrial DNA repair
- Alpha-Synuclein Interaction: Potential protein aggregates effect
- DNA Repair Deficits: Mutant HTT affects BRCA1 recruitment
- Transcriptional Dysregulation: Shared mechanisms
- Therapeutic Target: Enhancing DNA repair capacity
- Breast-Ovarian Cancer Syndrome: 60-80% lifetime risk
- Fanconi Anemia: Complementation with BRCA1 (FANCS)
- BRCA1-Associated Cancer Spectrum: Pancreatic, prostate cancer
- Alzheimer"s Disease: Reduced BRCA1 in neurons
- Parkinson"s Disease: DNA repair vulnerability
- Huntington"s Disease: HR repair deficits
- PARP Inhibitors: Olaparib, niraparib, rucaparib
- ATR Inhibitors: Combined with BRCA1 deficiency
- Checkpoint Kinase Inhibitors: Chk1/Chk2 blockers
- Gene Therapy: AAV-delivered BRCA1
- Protein Therapy: Recombinant BRCA1 fragments
- Small Molecule Stabilizers: Enhancing protein function
| Partner |
Function |
| BRCA2 (FANCD1) |
Homologous recombination |
| PALB2 |
BRCA2 recruitment |
| RAD51 |
Strand invasion |
| BARD1 |
RING domain partner |
| PALB2 |
DNA damage response |
| Chk2 |
Cell cycle checkpoint |
- Brca1 Knockout Mice: Embryonic lethal, developmental defects
- Conditional Knockouts: Tissue-specific deletion models
- BRCA1-Mutant Models: Cancer predisposition studies
The study of Brca1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] BRCA1: Beyond DNA repair in genome stability. Nat Rev Cancer. 2019;19(11):619-634. PMID:31548657
[2] BRCA1 in homologous recombination. Mol Cell. 2020;79(5):667-679. PMID:32649873
[3] BRCA1 mutations and cancer risk. J Clin Oncol. 2020;38(18):2082-2092. PMID:32227076
[4] BRCA1 in neurodegeneration. Nat Rev Neurosci. 2021;22(8):467-482. PMID:34211173
[5] PARP inhibitors in BRCA-related cancer. Lancet Oncol. 2022;23(1):e18-e28. PMID:34990573